Spironolactone and acute mountain sickness.
Thirteen adults trekking in Nepal in 1974 to altitudes between 4,300 m and 5,500 m remained free from acute mountain sickness while taking spironolactone as a prophylactic measure. Two years previously five of these adults trekking at similar altitudes, but without treatment, had suffered from acute mountain sickness. The regime used was spironolactone in a dosage of 25 mg three times a day for two days preceding and during the periods spent at altitudes above 3,000 m.
D000208:Acute Disease; D000328:Adult; D000532:Altitude Sickness / Q000188:drug therapy / Q000517:prevention & control*; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D000860:Hypoxia / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009051:Mountaineering; D009390:Nepal; D013148:Spironolactone / Q000627:therapeutic use*; D013178:Sports Medicine
D013148:Spironolactone; D005665:Furosemide; D001241:Aspirin